<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01975220</url>
  </required_header>
  <id_info>
    <org_study_id>1276.13</org_study_id>
    <nct_id>NCT01975220</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets</brief_title>
  <official_title>Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (25mg/1000mg and 12.5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed
      fixed dose combination (FDC) tablets containing empagliflozin &amp; metformin and the single
      tablets of empagliflozin and metformin when administered singularly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC 0-tz); Empagliflozin</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz); Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-tz (Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point); Metformin</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>AUC 0-tz (area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point); Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Measured Concentration of the Analyte in Plasma); Empagliflozin</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Cmax (maximum measured concentration of the analyte in plasma); Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Measured Concentration of the Analyte in Plasma); Metformin</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Cmax (maximum measured concentration of the analyte in plasma); Metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Empagliflozin</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Metformin</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Metformin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High dose, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin/Metformin XR, FDC</intervention_name>
    <description>Experimental: high dose empagliflozin/metformin XR, FDC tablet</description>
    <arm_group_label>High dose, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin/Metformin XR FDC</intervention_name>
    <description>Experimental: low dose empagliflozin/metformin XR, FDC tablet</description>
    <arm_group_label>Low dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Empagliflozin/1000 mg Metformin XR, FDC</intervention_name>
    <description>Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet</description>
    <arm_group_label>High dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tablet Empagliflozin/2 tablets Metformin XR</intervention_name>
    <description>Active Comparator: 1x empagliflozin/2x metformin XR tablets</description>
    <arm_group_label>High dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tablet Empagliflozin/3 tablets Metformin XR</intervention_name>
    <description>Active Comparator: 1x empagliflozin/3x metformin XR tablets</description>
    <arm_group_label>Low dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tablet Empagliflozin/2 tablets Metformin XR</intervention_name>
    <description>Active Comparator: 1x empagliflozin/2x metformin XR tablets</description>
    <arm_group_label>High dose, fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males or females

          2. Age 18-50 years (incl)

          3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl)

          4. Subjects must be able to understand and comply with study requirements

        Exclusion criteria:

        Any deviation from healthy condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.13.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2013</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2017</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose, Fasted: 1 FDC Tablet First, Then 3 Single Tablets</title>
          <description>1 fixed dose combination (FDC) tablet first, then 3 single tablets under fasted conditions:
25 mg Empagliflozin/1000 mg Metformin extended release (XR), FDC: Experimental, high dose Empagliflozin/Metformin XR,FDC tablet;
1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 2x Metformin XR tablets</description>
        </group>
        <group group_id="P2">
          <title>High Dose, Fasted: 3 Single Tablets First, Then 1 FDC Tablet</title>
          <description>3 single tablets first, then 1 fixed dose combination (FDC) tablet under fasted conditions:
1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 2x Metformin XR tablets;
25 mg Empagliflozin/1000 mg Metformin XR, FDC: Experimental, high dose Empagliflozin/Metformin XR,FDC tablet</description>
        </group>
        <group group_id="P3">
          <title>High Dose, Fed: 1 FDC Tablet First, Then 3 Single Tablets</title>
          <description>1 fixed dose combination (FDC) tablet first, then 3 single tablets under fed conditions:
25 mg Empagliflozin/1000 mg Metformin XR, FDC: Experimental, high dose Empagliflozin/Metformin XR,FDC tablet;
1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 2x Metformin XR tablets</description>
        </group>
        <group group_id="P4">
          <title>High Dose, Fed: 3 Single Tablets First, Then 1 FDC Tablet</title>
          <description>3 single tablets first, then 1 fixed dose combination (FDC) tablet under fed conditions:
1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 2x Metformin XR tablets;
25 mg Empagliflozin/1000 mg Metformin XR, FDC: Experimental, high dose Empagliflozin/Metformin XR,FDC tablet</description>
        </group>
        <group group_id="P5">
          <title>Low Dose, Fasted: 2 FDC Tablets First, Then 4 Single Tablets</title>
          <description>2 fixed low dose combination (FDC) tablets first, then 4 single tablets under fasted conditions:
12.5 mg Empagliflozin / 750 mg Metformin XR FDC tablets: Experimental: low dose Empagliflozin/Metformin XR, 2 FDC tablets;
1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 3x Metformin XR tablets</description>
        </group>
        <group group_id="P6">
          <title>Low Dose, Fasted: 4 Single Tablets First, Then 2 FDC Tablets</title>
          <description>4 single tablets first, then 2 fixed low dose combination (FDC) tablets under fasted conditions:
1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 3x Metformin XR tablets;
12.5 mg Empagliflozin/750 mg Metformin XR FDC tablets: Experimental: low dose Empagliflozin/Metformin XR, 2 FDC tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Test Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Test Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): This patient set includes all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>High Dose, Fasted</title>
          <description>1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions:
25 mg Empagliflozin/1000 mg Metformin XR (extended release), FDC: Experimental, high dose Empagliflozin/Metformin XR,FDC tablet;
1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 2x Metformin XR tablets</description>
        </group>
        <group group_id="B2">
          <title>High Dose, Fed</title>
          <description>1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions:
25 mg Empagliflozin/1000 mg Metformin XR, FDC: Experimental, high dose Empagliflozin/Metformin XR,FDC tablet;
1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 2x Metformin XR tablets</description>
        </group>
        <group group_id="B3">
          <title>Low Dose, Fasted</title>
          <description>2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fasted conditions:
12.5 mg Empagliflozin / 750 mg Metformin XR FDC tablets: Experimental: low dose Empagliflozin/Metformin XR, 2 FDC tablets;
1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 3x Metformin XR tablets</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="8.7"/>
                    <measurement group_id="B2" value="34.2" spread="9.2"/>
                    <measurement group_id="B3" value="30.8" spread="8.4"/>
                    <measurement group_id="B4" value="32.5" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC 0-tz); Empagliflozin</title>
        <description>Area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz); Empagliflozin</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS): This set includes all subjects of the Treated set (TS) who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of Pharmacokinetic (PK) endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose, Fasted: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fasted: 25 mg Empagliflozin/1000 mg Metformin XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>High Dose, Fasted: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fasted: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O3">
            <title>High Dose, Fed: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fed: 25 mg Empagliflozin/1000 mg Metformin XR</description>
          </group>
          <group group_id="O4">
            <title>High Dose, Fed: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fed: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O5">
            <title>Low Dose, Fasted: 2 FDC Tablets</title>
            <description>2 FDC tablets, low dose, fasted: 12.5 mg Empagliflozin / 750 mg Metformin XR</description>
          </group>
          <group group_id="O6">
            <title>Low Dose, Fasted: 4 Single Tablets</title>
            <description>4 single tablets, low dose, fasted: 1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC 0-tz); Empagliflozin</title>
          <description>Area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz); Empagliflozin</description>
          <population>Pharmacokinetic set (PKS): This set includes all subjects of the Treated set (TS) who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of Pharmacokinetic (PK) endpoints.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6430" spread="22.3"/>
                    <measurement group_id="O2" value="6430" spread="21.7"/>
                    <measurement group_id="O3" value="5690" spread="21.0"/>
                    <measurement group_id="O4" value="5850" spread="19.6"/>
                    <measurement group_id="O5" value="7160" spread="19.5"/>
                    <measurement group_id="O6" value="7110" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>99.98</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.275</ci_lower_limit>
            <ci_upper_limit>102.751</ci_upper_limit>
            <estimate_desc>Adjusted geometric mean (GM) ratio(%) was calculated as GM of 'High dose, fasted:1 FDC tablet' divided by GM of 'High dose, fasted:3 single tablets’.The 'standard deviation' is actually intra-individual geometric coefficient of variation (gCV (%)).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>97.09</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.857</ci_lower_limit>
            <ci_upper_limit>100.436</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fed: 1 FDC tablet' divided by the geometric mean of 'High dose, fed: 3 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>100.70</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.28</ci_lower_limit>
            <ci_upper_limit>103.18</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'Low dose, fasted: 2 FDC tablets' divided by the geometric mean of 'Low dose, fasted: 4 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-tz (Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point); Metformin</title>
        <description>AUC 0-tz (area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point); Metformin</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose, Fasted: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fasted: 25 mg Empagliflozin/1000 mg Metformin XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>High Dose, Fasted: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fasted: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O3">
            <title>High Dose, Fed: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fed: 25 mg Empagliflozin/1000 mg Metformin XR</description>
          </group>
          <group group_id="O4">
            <title>High Dose, Fed: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fed: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O5">
            <title>Low Dose, Fasted: 2 FDC Tablets</title>
            <description>2 FDC tablets, low dose, fasted: 12.5 mg Empagliflozin / 750 mg Metformin XR</description>
          </group>
          <group group_id="O6">
            <title>Low Dose, Fasted: 4 Single Tablets</title>
            <description>4 single tablets, low dose, fasted: 1 x 25 mg tablets Empagliflozin / 3 x 500 mg tablets Metformin XR</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-tz (Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point); Metformin</title>
          <description>AUC 0-tz (area under the concentration -time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point); Metformin</description>
          <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6350" spread="32.8"/>
                    <measurement group_id="O2" value="6700" spread="28.9"/>
                    <measurement group_id="O3" value="13000" spread="23.6"/>
                    <measurement group_id="O4" value="13100" spread="21.1"/>
                    <measurement group_id="O5" value="10200" spread="38.5"/>
                    <measurement group_id="O6" value="10300" spread="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>0.0256</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>94.65</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>28.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.29</ci_lower_limit>
            <ci_upper_limit>108.88</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fasted: 1 FDC tablet' divided by the geometric mean of 'High dose, fasted: 3 single tablets'. The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>99.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.25</ci_lower_limit>
            <ci_upper_limit>103.26</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fed: 1 FDC tablet' divided by the geometric mean of 'High dose, fed: 3 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>0.0020</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>99.76</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.65</ci_lower_limit>
            <ci_upper_limit>112.27</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'Low dose, fasted: 2 FDC tablets' divided by the geometric mean of 'Low dose, fasted: 4 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Empagliflozin</title>
        <description>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Empagliflozin</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose, Fasted: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fasted: 25 mg Empagliflozin/1000 mg Metformin XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>High Dose, Fasted: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fasted: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O3">
            <title>High Dose, Fed: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fed: 25 mg Empagliflozin/1000 mg Metformin XR</description>
          </group>
          <group group_id="O4">
            <title>High Dose, Fed: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fed: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O5">
            <title>Low Dose, Fasted: 2 FDC Tablets</title>
            <description>2 FDC tablets, low dose, fasted: 12.5 mg Empagliflozin / 750 mg Metformin XR</description>
          </group>
          <group group_id="O6">
            <title>Low Dose, Fasted: 4 Single Tablets</title>
            <description>4 single tablets, low dose, fasted: 1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Empagliflozin</title>
          <description>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Empagliflozin</description>
          <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6510" spread="22.9"/>
                    <measurement group_id="O2" value="6490" spread="21.6"/>
                    <measurement group_id="O3" value="5800" spread="21.8"/>
                    <measurement group_id="O4" value="5970" spread="20.5"/>
                    <measurement group_id="O5" value="7240" spread="19.7"/>
                    <measurement group_id="O6" value="7180" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>100.10</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.555</ci_lower_limit>
            <ci_upper_limit>102.719</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fasted: 1 FDC tablet' divided by the geometric mean of 'High dose, fasted: 3 single tablets'. The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>97.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.622</ci_lower_limit>
            <ci_upper_limit>100.531</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fed: 1 FDC tablet' divided by the geometric mean of 'High dose, fed: 3 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>100.78</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.36</ci_lower_limit>
            <ci_upper_limit>103.27</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'Low dose, fasted: 2 FDC tablets' divided by the geometric mean of 'Low dose, fasted: 4 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Measured Concentration of the Analyte in Plasma); Empagliflozin</title>
        <description>Cmax (maximum measured concentration of the analyte in plasma); Empagliflozin</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose, Fasted: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fasted: 25 mg Empagliflozin/1000 mg Metformin XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>High Dose, Fasted: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fasted: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O3">
            <title>High Dose, Fed: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fed: 25 mg Empagliflozin/1000 mg Metformin XR</description>
          </group>
          <group group_id="O4">
            <title>High Dose, Fed: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fed: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O5">
            <title>Low Dose, Fasted: 2 FDC Tablets</title>
            <description>2 FDC tablets, low dose, fasted: 12.5 mg Empagliflozin / 750 mg Metformin XR</description>
          </group>
          <group group_id="O6">
            <title>Low Dose, Fasted: 4 Single Tablets</title>
            <description>4 single tablets, low dose, fasted: 1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Measured Concentration of the Analyte in Plasma); Empagliflozin</title>
          <description>Cmax (maximum measured concentration of the analyte in plasma); Empagliflozin</description>
          <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="886" spread="27.3"/>
                    <measurement group_id="O2" value="810" spread="28.1"/>
                    <measurement group_id="O3" value="559" spread="29.0"/>
                    <measurement group_id="O4" value="601" spread="25.0"/>
                    <measurement group_id="O5" value="1010" spread="27.0"/>
                    <measurement group_id="O6" value="963" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>0.0072</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>109.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>17.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.892</ci_lower_limit>
            <ci_upper_limit>119.100</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fasted: 1 FDC tablet' divided by the geometric mean of 'High dose, fasted: 3 single tablets'. The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>0.0004</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>92.42</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.781</ci_lower_limit>
            <ci_upper_limit>98.428</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fed: 1 FDC tablet' divided by the geometric mean of 'High dose, fed: 3 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing</non_inferiority_desc>
            <p_value>0.0014</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>105.37</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>17.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.600</ci_lower_limit>
            <ci_upper_limit>114.942</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'Low dose, fasted: 2 FDC tablets' divided by the geometric mean of 'Low dose, fasted: 4 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Measured Concentration of the Analyte in Plasma); Metformin</title>
        <description>Cmax (maximum measured concentration of the analyte in plasma); Metformin</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose, Fasted: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fasted: 25 mg Empagliflozin/1000 mg Metformin XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>High Dose, Fasted: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fasted: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O3">
            <title>High Dose, Fed: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fed: 25 mg Empagliflozin/1000 mg Metformin XR</description>
          </group>
          <group group_id="O4">
            <title>High Dose, Fed: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fed: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O5">
            <title>Low Dose, Fasted: 2 FDC Tablets</title>
            <description>2 FDC tablets, low dose, fasted: 12.5 mg Empagliflozin / 750 mg Metformin XR</description>
          </group>
          <group group_id="O6">
            <title>Low Dose, Fasted: 4 Single Tablets</title>
            <description>4 single tablets, low dose, fasted: 1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Measured Concentration of the Analyte in Plasma); Metformin</title>
          <description>Cmax (maximum measured concentration of the analyte in plasma); Metformin</description>
          <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="822" spread="37.4"/>
                    <measurement group_id="O2" value="851" spread="28.8"/>
                    <measurement group_id="O3" value="1180" spread="27.4"/>
                    <measurement group_id="O4" value="1070" spread="22.8"/>
                    <measurement group_id="O5" value="1300" spread="34.4"/>
                    <measurement group_id="O6" value="1330" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>0.0198</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>96.65</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.337</ci_lower_limit>
            <ci_upper_limit>112.079</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fasted: 1 FDC tablet' divided by the geometric mean of 'High dose, fasted: 3 single tablets'. The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>0.0007</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>110.17</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>103.809</ci_lower_limit>
            <ci_upper_limit>116.926</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fed: 1 FDC tablet' divided by the geometric mean of 'High dose, fed: 3 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>0.0037</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>97.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>23.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.942</ci_lower_limit>
            <ci_upper_limit>109.734</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'Low dose, fasted: 2 FDC tablets' divided by the geometric mean of 'Low dose, fasted: 4 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Metformin</title>
        <description>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Metformin</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2h 30min, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose, Fasted: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fasted: 25 mg Empagliflozin/1000 mg Metformin XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>High Dose, Fasted: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fasted: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O3">
            <title>High Dose, Fed: 1 FDC Tablet</title>
            <description>1 FDC tablet, high dose, fed: 25 mg Empagliflozin/1000 mg Metformin XR</description>
          </group>
          <group group_id="O4">
            <title>High Dose, Fed: 3 Single Tablets</title>
            <description>3 single tablets, high dose, fed: 1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR</description>
          </group>
          <group group_id="O5">
            <title>Low Dose, Fasted: 2 FDC Tablets</title>
            <description>2 FDC tablets, low dose, fasted: 12.5 mg Empagliflozin / 750 mg Metformin XR</description>
          </group>
          <group group_id="O6">
            <title>Low Dose, Fasted: 4 Single Tablets</title>
            <description>4 single tablets, low dose, fasted: 1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity); Metformin</title>
          <description>AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Metformin</description>
          <population>PKS: This set includes all subjects of the TS who provided at least one observation for at least one primary endpoint and had no important protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6490" spread="35.2"/>
                    <measurement group_id="O2" value="6790" spread="29.6"/>
                    <measurement group_id="O3" value="13200" spread="24.0"/>
                    <measurement group_id="O4" value="13200" spread="21.6"/>
                    <measurement group_id="O5" value="10500" spread="41.9"/>
                    <measurement group_id="O6" value="10400" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>0.0254</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>95.40</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.42</ci_lower_limit>
            <ci_upper_limit>110.44</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fasted: 1 FDC tablet' divided by the geometric mean of 'High dose, fasted: 3 single tablets'. The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>99.63</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.21</ci_lower_limit>
            <ci_upper_limit>103.17</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'High dose, fed: 1 FDC tablet' divided by the geometric mean of 'High dose, fed: 3 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing.</non_inferiority_desc>
            <p_value>0.0029</p_value>
            <method>ANOVA</method>
            <param_type>Adjusted geometric mean ratio (%)</param_type>
            <param_value>101.06</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.70</ci_lower_limit>
            <ci_upper_limit>113.86</ci_upper_limit>
            <estimate_desc>The adjusted geometric mean ratio (%) was calculated as the geometric mean of 'Low dose, fasted: 2 FDC tablets' divided by the geometric mean of 'Low dose, fasted: 4 single tablets'.
The 'standard deviation' is actually the intra-individual gCV (%).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first trial medication intake until next intake or the end-of-trial visit, 10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose, Fasted: 1 FDC Tablet</title>
          <description>1 fixed dose combination (FDC) tablet under fasted conditions:
25 mg Empagliflozin/1000 mg Metformin XR (extended release), FDC: Experimental, high dose Empagliflozin/Metformin XR, FDC tablet</description>
        </group>
        <group group_id="E2">
          <title>High Dose, Fasted: 3 Single Tablets</title>
          <description>3 single tablets under fasted conditions:
1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 2x Metformin XR tablets</description>
        </group>
        <group group_id="E3">
          <title>High Dose, Fed: 1 FDC Tablet</title>
          <description>1 fixed dose combination (FDC) tablet under fed conditions:
25 mg Empagliflozin/1000 mg Metformin XR, FDC: Experimental, high dose Empagliflozin/Metformin XR,FDC tablet</description>
        </group>
        <group group_id="E4">
          <title>High Dose, Fed: 3 Single Tablets</title>
          <description>3 single tablets under fed conditions:
1 x 25 mg tablet Empagliflozin / 2 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 2x Metformin XR tablets</description>
        </group>
        <group group_id="E5">
          <title>Low Dose, Fasted: 2 FDC Tablets</title>
          <description>2 fixed dose combination (FDC) tablets under fasted conditions:
12.5 mg Empagliflozin / 750 mg Metformin XR FDC tablets: Experimental: low dose Empagliflozin/Metformin XR, 2 FDC tablets</description>
        </group>
        <group group_id="E6">
          <title>Low Dose, Fasted: 4 Single Tablets</title>
          <description>4 single tablets under fed conditions:
1 x 25 mg tablet Empagliflozin / 3 x 500 mg tablets Metformin XR: Active Comparator: 1x Empagliflozin / 3x Metformin XR tablets</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

